David Grayzel
InvestorManaging Director at Atlas Venture
Cambridge, Massachusetts, United States
Writes $500K – $5M checks · typically $2M
About
David Grayzel is a physician-turned-VC who repeatedly co-founds biotech companies and serves as CEO or chair, focusing on immune-system therapeutics in autoimmunity and oncology (Surface Oncology, Q32 Bio, Comanche Biopharma).
Invests in
BiotechHealthtech
Experience
- Atlas VenturePartnercurrent2014 — presentCambridge, MA
- Atlas Venture Development Corp.Managing Directorcurrent2010 — present
- Infinity PharmaceuticalsVP Clinical Development and Medical Affairs2002 — 2010
- Dyax CorpDirector Corporate Development and Business Operations2000 — 2002
- Massachusetts General HospitalIntern, Resident1997 — 2000
Education
- Harvard Medical SchoolMD1992 — 1997
- Stanford UniversityBA
Same school
Also attended Harvard Medical School113
+ 107 more
Also attended Stanford University1,575
+ 1,569 more
Shared employers
Also worked at Infinity Pharmaceuticals9
+ 3 more
Also worked at Massachusetts General Hospital44
+ 38 more
Deals · 4
Triana Biomedicines, Inc.Board seat
via Atlas Venture · filed Dec 2025 · $120.1M raise
Xilio TherapeuticsBoard seat
via Atlas Venture · filed Feb 2021 · $95M raise
Aerovate Therapeutics, Inc.Board seat
via Atlas Venture · filed Aug 2020 · $75.8M raise
Akriveia TherapeuticsBoard seat
via Atlas Venture · filed Jan 2018 · $22.5M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Atlas Venture
Network5
Investors connected to David in public investor directories — a warm-intro map.

.png)

























